Pfizer PF-06688992 in Patients With Stage III or Stage IV Melanoma

NCT03159117

Last updated date
Study Location
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Melanoma
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Histological diagnosis of melanoma confirmed at MSKCC

- Measurable unresectable Stage III or IV Malignant Melanoma and Response Criteria in Solid Tumors [RECIST], Version 1.1.

- Patients must have progressed on prior approved checkpoint inhibitor therapy, not tolerated approved checkpoint inhibitor therapy, or have a contraindication to approved checkpoint inhibitors. Patients with stable disease after approved checkpoint inhibitor therapy will also be eligible.

- Patients whose melanomas harbor a BRAF V600E or V600K mutation must have progressed on a RAF inhibitor. Patients who had to discontinue RAF inhibitor therapy because of toxicity but who did not progress will be eligible unless they responded to therapy. In that case, they will not be eligible unless they progress.

- Age ≥ 18 years

- ECOG performance status 0-1.

- Adequate Bone Marrow Function as defined by:

°≥1,500/mm^3 or ≥ 1.5 x 10^9/L;

- Platelets ≥ 100,000/mm3 or ≥ 100 x 109/L;

- Hemoglobin ≥ 9 g/dL.

- Adequate Renal Function as defined by:

- Serum creatinine ≤ 1.5 x upper limit of normal (ULN); or

- Estimated creatinine clearance ≥ 60 mL/min as calculated using the method standard for the institution.

- Adequate Liver Function as defined by:

- Total serum bilirubin ≤ 1.5 x ULN unless the patient has documented Gilbert syndrome;

- Aspartate and Alanine Aminotransferase (AST & ALT) ≤ 2.5 x ULN; ≤ 5.0 x ULN if there is liver involvement secondary to tumor;

- Alkaline phosphatase ≤ 2.5 x ULN; (≤ 5 x ULN in case of bone metastasis).

- QTc interval < 470 msec.

- Recovery from all prior surgical or adjuvant treatment-related toxicities, to Baseline status, or a CTCAE Grade of 0 or 1, except for toxicities not considered a safety risk, such as alopecia. Post-surgical pain will not be considered a basis for exclusion.

- Negative serum/urine pregnancy test (for women of childbearing potential).

- Male and female patients of childbearing potential must agree to use a highly effective method of contraception throughout the study and for at least 28 days after the last dose of assigned treatment. A patient is of childbearing potential if, in the opinion of the investigator, he/she is biologically capable of having children and is sexually active.

- Evidence of a signed and dated informed consent document indicating that the patient has been informed of all pertinent aspects of the study.

- Willingness and ability to comply with the study scheduled visits, treatment plans, laboratory tests and other procedures.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Patients with known symptomatic brain metastases requiring steroids.


- Patients with previously diagnosed brain metastases are eligible as long as they do
not require CNS-directed therapy (including corticosteroids). If the patient has had
radiation therapy or surgery, then they should have completed treatment and have
discontinued corticosteroids for at least 2 weeks and must be neurologically stable.


- Patients with uveal melanoma will not be eligible as these tumors show low expression
of GD3.


- Major surgery, radiation therapy or systemic anti-cancer therapy within 2 weeks of
starting study treatment.


- Presence of ≥ Grade 2 peripheral neuropathy.


- Significant prior infusion reaction to monoclonal antibodies that required treatment
with systemic steroids.


- Active and clinically significant bacterial, fungal or viral infection.


- Known infections with hepatitis B (HBV) or hepatitis C (HCV),


- Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome
(AIDS)-related illness not controlled (with undetectable viral load) on HAART
therapy. Patients on HAART with undetectable viral loads may be eligible per PI
judgment.


- Pregnant or breastfeeding; males and females of childbearing potential who are
unwilling or unable to use a highly effective method of contraception as outlined in
this protocol for the duration of the study and for at least 28 days after last dose
of investigational product.


- Patients currently receiving active treatment for melanoma.


- Any of the following in the previous 6 months: myocardial infarction, severe/unstable
angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure,
cerebrovascular accident, transient ischemic attack.


- Any ongoing cardiac dysrhythmias of NCI CTCAE Grade >2, NCI CTCAE Grade 4 atrial
fibrillation, or QTcF interval >470 msec, except for documented Right Bundle Branch
Block, at screening.


- Chronic Bronchitis or Emphysema requiring oxygen therapy within the last 6 months.


- Other severe acute or chronic medical or psychiatric condition, including recent
(within the past year) or active suicidal ideation or behavior, or laboratory
abnormality or uncontrolled hypertension that may increase the risk associated with
study participation or investigational product administration or may interfere with
the interpretation of study results and, in the judgment of the investigator, would
make the patient inappropriate for entry into this study.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

pfizer-logoClinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

MelanomaEncorafenib and Binimetinib Plus Pembrolizumab Versus Pembrolizumab for BRAF V600E/K Positive Melanoma
NCT04657991
  1. Orlando, Florida
  2. Orlando, Florida
  3. Orlando, Florida
  4. Temple, Texas
  5. Aventura, Florida
  6. Knoxville, Tennessee
  7. Nashville, Tennessee
  8. Nashville, Tennessee
ALL GENDERS
18 Years+
years
MULTIPLE SITES
MelanomaStudy Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma
NCT01909453
  1. Birmingham, Alabama
  2. Birmingham, Alabama
  3. Birmingham, Alabama
  4. Birmingham, Alabama
  5. Fayetteville, Arkansas
  6. Rogers, Arkansas
  7. Orange County, California
  8. Orange, California
  9. Orange, California
  10. Aurora, Colorado
  11. Boulder, Colorado
  12. Colorado Springs, Colorado
  13. Denver, Colorado
  14. Lakewood, Colorado
  15. Parker, Colorado
  16. Pueblo, Colorado
  17. Chicago, Illinois
  18. Chicago, Illinois
  19. Chicago, Illinois
  20. Chicago, Illinois
  21. Goshen, Indiana
  22. Goshen, Indiana
  23. Grand Rapids, Michigan
  24. Grand Rapids, Michigan
  25. Grand Rapids, Michigan
  26. Jackson, Mississippi
  27. Jackson, Mississippi
  28. Hackensack, New Jersey
  29. Rochester, New York
  30. Dallas, Texas
  31. Burlington, Vermont
  32. Burlington, Vermont
  33. Burlington, Vermont
  34. Alexandria, Virginia
  35. Arlington, Virginia
  36. Fairfax, Virginia
  37. Fairfax, Virginia
  38. Fairfax, Virginia
  39. Fairfax, Virginia
  40. Falls Church, Virginia
  41. Gainesville, Virginia
  42. Leesburg, Virginia
  43. Leesburg, Virginia
  44. Woodbridge, Virginia
  45. Wenatchee, Washington
  46. Caba, Buenos Aires
  47. Buenos Aires, Ciudad Autónoma DE Buenosaires
  48. Buenos Aires, Ciudad Autónoma DE Buenosaires
  49. Buenos Aires, Ciudad Autónoma DE Buenosaires
  50. Buenos Aires, Ciudad Autónoma DE Buenosaires
  51. Buenos Aires, Ciudad Autónoma DE Buenosaires
  52. Buenos Aires, Ciudad Autónoma DE Buenosaires
  53. Gateshead, New South Wales
  54. Southport, Queensland
  55. Southport, Queensland
  56. Southport, Queensland
  57. Woolloongabba, Queensland
  58. Melbourne, Victoria
  59. Prahran, Victoria
  60. Nedlands, Western Australia
  61. Recife, Pernambuco
  62. Ijuí, RIO Grande DO SUL
  63. Porto Alegre, RIO Grande DO SUL
  64. Barretos, SAO Paulo
  65. Natal,
  66. Rio de Janeiro,
  67. Sao Paulo,
  68. Calgary, Alberta
  69. Toronto, Ontario
  70. Toronto, Ontario
  71. Toronto, Ontario
  72. Montreal, Quebec
  73. Montreal, Quebec
  74. Montreal, Quebec
  75. Montreal, Quebec
  76. Québec, Quebec
  77. Bogotá, Distrito Capital DE Bogotá
  78. Bogotá, Pbx (57-1)
  79. Brno, Jihomoravský KRAJ
  80. Praha 10, Praha, Hlavní Mesto
  81. Praha 2, Praha, Hlavní Mesto
  82. Brno,
  83. Olomouc,
  84. Ostrava Poruba,
  85. Praha,
  86. Nice, Alpes-maritimes
  87. Bordeaux, Gironde
  88. Grenoble, Isère
  89. Reims, Marne
  90. Lille, Nord
  91. Lyon, Rhone
  92. Lyon, Rhône
  93. Le Mans, Sarthe
  94. Villejuif, Val-de-marne
  95. Boulogne-Billancourt,
  96. Lille,
  97. Lyon,
  98. Nice,
  99. Paris,
  100. Paris,
  101. Paris,
  102. Paris,
  103. Pierre-bénite,
  104. Strasbourg,
  105. Templemars,
  106. Villejuif,
  107. Freiburg im Breisgau, Baden-württemberg
  108. Heidelberg, Baden-württemberg
  109. Mannheim, Baden-württemberg
  110. Tübingen, Baden-württemberg
  111. Ulm, Baden-württemberg
  112. München, Bayern
  113. Regensburg, Bayern
  114. Regensburg, Bayern
  115. Würzburg, Bayern
  116. Frankfurt, Hessen
  117. Kassel, Hessen
  118. Kassel, Hessen
  119. Buxtehude, Niedersachsen
  120. Buxtehude, Niedersachsen
  121. Bonn, Nordrhein-westfalen
  122. Minden, Nordrhein-westfalen
  123. Minden, Nordrhein-westfalen
  124. Mainz, Rheinland-pfalz
  125. Magdeburg, Sachsen-anhalt
  126. Dresden, Sachsen
  127. Leipzig, Sachsen
  128. Berlin, Schleswig-holstein
  129. Luebeck, Schleswig-holstein
  130. Lübeck, Schleswig-holstein
  131. Berlin,
  132. Bonn,
  133. Bonn,
  134. Dresden,
  135. Dresden,
  136. Erfurt,
  137. Erfurt,
  138. Essen,
  139. Freiburg,
  140. Gera,
  141. Gera,
  142. Gera,
  143. Hamburg,
  144. Hannover,
  145. Hannover,
  146. Hannover,
  147. Heidelberg,
  148. Homburg,
  149. Kiel,
  150. Lübeck,
  151. Magdeburg,
  152. Magdeburg,
  153. Mainz,
  154. Mannheim,
  155. Minden,
  156. Münster,
  157. Nürnberg,
  158. Regensburg,
  159. Tübingen,
  160. Ulm,
  161. Ulm,
  162. Athens, Attiki
  163. Athens,
  164. Athens,
  165. Piraeus,
  166. Debrecen, Hajdú-bihar
  167. Budapest,
  168. Budapest,
  169. Szolnok,
  170. Ramat Gan, Tel-aviv
  171. Haifa,
  172. Jerusalem,
  173. Torrette Site, Ancona
  174. Napoli, Campania
  175. Roma, Lazio
  176. Roma, Lazio
  177. Lecco, Lombardia
  178. Milan, Lombardia
  179. Monza, Lombardia
  180. Rozzano, Lombardia
  181. Rozzano, Lombardia
  182. Candiolo, Torino
  183. Pisa, Toscana
  184. Terni, Umbria
  185. Padua, Veneto
  186. Bari,
  187. Bergamo,
  188. Bologna,
  189. Genoa,
  190. Milano,
  191. Napoli,
  192. Padova,
  193. Pavia,
  194. Ragusa,
  195. Siena,
  196. Torino,
  197. Fukuoka-shi, Fukuoka
  198. Matsumoto, Nagano
  199. Chuo-ku, Tokyo
  200. Niigata,
  201. Osaka, Ôsaka
  202. Gangnam-Gu, Seoul Teugbyeolsi
  203. Songpa-Gu, Seoul Teugbyeolsi
  204. Seoul,
  205. Seoul,
  206. Seoul,
  207. Seoul,
  208. Mexico,
  209. Mexico,
  210. Nijmegen, Gelderland
  211. Heerlen, Limburg
  212. Amsterdam, Noord Holland
  213. Breda, Noord-brabant
  214. Eindhoven, Noord-brabant
  215. Veldhoven, Noord-brabant
  216. Enschede, Overijssel
  217. Zwolle, Overijssel
  218. Groningen,
  219. Leiden,
  220. Maastricht,
  221. Rotterdam,
  222. Rotterdam,
  223. Sittard-Geleen,
  224. Oslo,
  225. Oslo,
  226. Oslo,
  227. Warsaw, Mazowieckie
  228. Warszawa, Mazowieckie
  229. Warszawa,
  230. Lisbon, Lisboa
  231. Porto, Proto
  232. Almada,
  233. Lisboa,
  234. Lisboa,
  235. Lisboa,
  236. Porto,
  237. Moscow,
  238. St. Petersburg,
  239. Singapore,
  240. Singapore,
  241. Singapore,
  242. Bratislava,
  243. Bratislava,
  244. Bratislava,
  245. Poprad,
  246. Pretoria,
  247. Pretoria,
  248. Jerez De La Frontera, Andalucía
  249. Oviedo, Asturias
  250. Barcelona, Cataluña
  251. El Palmar, Murcia
  252. Pamplona, Navarra
  253. Pamplona, Navarra
  254. Alicante,
  255. Badalona,
  256. Barcelona,
  257. Barcelona,
  258. Barcelona,
  259. Barcelona,
  260. Donostia-san Sebastián,
  261. Dos Hermanas,
  262. Granada,
  263. La Coruna,
  264. Lleida,
  265. Lleida,
  266. Madrid,
  267. Madrid,
  268. Madrid,
  269. Madrid,
  270. Majadahonda,
  271. Malaga,
  272. Sevilla,
  273. Sevilla,
  274. Sevilla,
  275. Valencia,
  276. Göteborg,
  277. Lund,
  278. Solna,
  279. Uppsala,
  280. Zurich, Zürich (DE)
  281. Bern,
  282. Zürich,
  283. Zürich,
  284. Zürich,
  285. Bornova,
  286. Izmir,
  287. Izmir,
  288. Cambridge, Cambridgeshire
  289. Preston, Lancashire
  290. London, London, CITY OF
  291. Guildford, Surrey
  292. Bebington, Wirral
  293. Sheffield, York
  294. Broomfield,
  295. Leeds,
  296. London,
  297. Manchester,
  298. Oxford,
  299. Oxford,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
MelanomaPfizer PF-06688992 in Patients With Stage III or Stage IV Melanoma
NCT03159117
  1. New York, New York
ALL GENDERS
18 Years+
years
MULTIPLE SITES
MelanomaPhase I Oncovir Poly IC:LC and NY-ESO-1/gp100
NCT01008527
  1. Tampa, Florida
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Pfizer PF-06688992 in Patients With Stage III or Stage IV Melanoma
Official Title  ICMJE A Phase I Open-Label Dose Escalation of GD3 ADC (Pfizer PF-06688992) in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma (B802WI209568)
Brief Summary

The purpose of this research study is to learn about the safety and effectiveness of the study drug, PF-06688992. Before this study, PF-06688992 has never been given to people.

PF-06688992 is a targeted therapy for people with cancer. The investigators linked a chemotherapy drug to an antibody (protein found in the blood). The antibody will connect to GD3 which is found on most melanomas but on very few other cells in the body. The investigators hope that in this way, it will deliver this chemotherapy directly to the melanoma and not to normal tissues.

Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description:
This is a Phase 1 non-randomized, open-label, single-center, single-arm multiple dose escalation
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Melanoma
Intervention  ICMJE Drug: PF-06688992
(PF-06688992) will be administered on Day 1 of each 21-day cycle per the Dose Preparation and Administration Instructions (DAI) located in the Investigational Product Manual (Appendix 4Appendix 3) as an IV infusion over approximately 60 minutes. A cycle is defined as the time from Day 1 dose to the next Day 1 dose. If there are no treatment delays, a cycle will be 21 days. Each patient may receive PF-06688992 until disease progression, unacceptable toxicity, withdrawal of consent, or study termination
Other Name: GD3 ADC
Study Arms  ICMJE Experimental: PF 06688992
This clinical study will be a dose-finding phase I study in which patients will be treated with various doses of Pfizer PF-06688992 using a Bayesian dose escalation scheme.
Intervention: Drug: PF-06688992
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: May 20, 2019)
7
Original Estimated Enrollment  ICMJE
 (submitted: May 17, 2017)
40
Actual Study Completion Date  ICMJE January 10, 2020
Actual Primary Completion Date January 10, 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Histological diagnosis of melanoma confirmed at MSKCC
  • Measurable unresectable Stage III or IV Malignant Melanoma and Response Criteria in Solid Tumors [RECIST], Version 1.1.
  • Patients must have progressed on prior approved checkpoint inhibitor therapy, not tolerated approved checkpoint inhibitor therapy, or have a contraindication to approved checkpoint inhibitors. Patients with stable disease after approved checkpoint inhibitor therapy will also be eligible.
  • Patients whose melanomas harbor a BRAF V600E or V600K mutation must have progressed on a RAF inhibitor. Patients who had to discontinue RAF inhibitor therapy because of toxicity but who did not progress will be eligible unless they responded to therapy. In that case, they will not be eligible unless they progress.
  • Age ? 18 years
  • ECOG performance status 0-1.
  • Adequate Bone Marrow Function as defined by:

    °?1,500/mm^3 or ? 1.5 x 10^9/L;

    • Platelets ? 100,000/mm3 or ? 100 x 109/L;
    • Hemoglobin ? 9 g/dL.
  • Adequate Renal Function as defined by:

    • Serum creatinine ? 1.5 x upper limit of normal (ULN); or
    • Estimated creatinine clearance ? 60 mL/min as calculated using the method standard for the institution.
  • Adequate Liver Function as defined by:

    • Total serum bilirubin ? 1.5 x ULN unless the patient has documented Gilbert syndrome;
    • Aspartate and Alanine Aminotransferase (AST & ALT) ? 2.5 x ULN; ? 5.0 x ULN if there is liver involvement secondary to tumor;
    • Alkaline phosphatase ? 2.5 x ULN; (? 5 x ULN in case of bone metastasis).
  • QTc interval < 470 msec.
  • Recovery from all prior surgical or adjuvant treatment-related toxicities, to Baseline status, or a CTCAE Grade of 0 or 1, except for toxicities not considered a safety risk, such as alopecia. Post-surgical pain will not be considered a basis for exclusion.
  • Negative serum/urine pregnancy test (for women of childbearing potential).
  • Male and female patients of childbearing potential must agree to use a highly effective method of contraception throughout the study and for at least 28 days after the last dose of assigned treatment. A patient is of childbearing potential if, in the opinion of the investigator, he/she is biologically capable of having children and is sexually active.
  • Evidence of a signed and dated informed consent document indicating that the patient has been informed of all pertinent aspects of the study.
  • Willingness and ability to comply with the study scheduled visits, treatment plans, laboratory tests and other procedures.

Exclusion Criteria:

  • Patients with known symptomatic brain metastases requiring steroids.
  • Patients with previously diagnosed brain metastases are eligible as long as they do not require CNS-directed therapy (including corticosteroids). If the patient has had radiation therapy or surgery, then they should have completed treatment and have discontinued corticosteroids for at least 2 weeks and must be neurologically stable.
  • Patients with uveal melanoma will not be eligible as these tumors show low expression of GD3.
  • Major surgery, radiation therapy or systemic anti-cancer therapy within 2 weeks of starting study treatment.
  • Presence of ? Grade 2 peripheral neuropathy.
  • Significant prior infusion reaction to monoclonal antibodies that required treatment with systemic steroids.
  • Active and clinically significant bacterial, fungal or viral infection.

    • Known infections with hepatitis B (HBV) or hepatitis C (HCV),
    • Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness not controlled (with undetectable viral load) on HAART therapy. Patients on HAART with undetectable viral loads may be eligible per PI judgment.
  • Pregnant or breastfeeding; males and females of childbearing potential who are unwilling or unable to use a highly effective method of contraception as outlined in this protocol for the duration of the study and for at least 28 days after last dose of investigational product.
  • Patients currently receiving active treatment for melanoma.
  • Any of the following in the previous 6 months: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack.
  • Any ongoing cardiac dysrhythmias of NCI CTCAE Grade >2, NCI CTCAE Grade 4 atrial fibrillation, or QTcF interval >470 msec, except for documented Right Bundle Branch Block, at screening.
  • Chronic Bronchitis or Emphysema requiring oxygen therapy within the last 6 months.
  • Other severe acute or chronic medical or psychiatric condition, including recent (within the past year) or active suicidal ideation or behavior, or laboratory abnormality or uncontrolled hypertension that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03159117
Other Study ID Numbers  ICMJE 17-165
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD:Undecided
Responsible Party Memorial Sloan Kettering Cancer Center
Study Sponsor  ICMJE Memorial Sloan Kettering Cancer Center
Collaborators  ICMJE Pfizer
Investigators  ICMJE
Principal Investigator:Paul Chapman, MDMemorial Sloan Kettering Cancer Center
PRS Account Memorial Sloan Kettering Cancer Center
Verification Date January 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP